Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Health Canada has become the most recent national drug regulator to issue a warning about Actos and bladder cancer. Last month, the agency warned that interim results from a 10-year-study indicated that patients taking Actos for more than a year faced an increased risk of bladder cancer. Health Canada also announced that Takeda Pharmaceuticals, the maker of Actos, had agreed to update the Actos label in Canada to reflect this risk.

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.